Primary Hyperparathyroidism: Proceed to Parathyroidectomy
This patient has primary hyperparathyroidism (PHPT) with osteopenia as a target organ complication, and should be referred to an endocrine surgeon for parathyroidectomy. 1
Diagnostic Confirmation
Your patient meets clear diagnostic criteria for PHPT:
- Persistent hypercalcemia (calcium 10.8 mg/dL, normal upper limit ~10.5)
- Elevated or inappropriately normal PTH (82 pg/mL in the setting of hypercalcemia)
- Adequate vitamin D status (60 ng/mL) rules out vitamin D deficiency as a confounding factor
The vitamin D level of 60 ng/mL is particularly important here—it eliminates the common diagnostic pitfall where severe vitamin D deficiency can mask hypercalcemia or cause secondary hyperparathyroidism that mimics PHPT 1, 2. With adequate vitamin D repletion, the persistent elevation of both calcium and PTH confirms autonomous parathyroid function.
Surgical Indication: Osteopenia
The presence of osteopenia constitutes a target organ complication and is an absolute indication for surgery 1. The 2025 French expert consensus explicitly states that surgery is recommended "as soon as there are clinical consequences," and bone disease (osteopenia/osteoporosis) qualifies as such a consequence 1.
This is not "asymptomatic" PHPT—the patient has symptomatic disease affecting bone health. At age 60, a postmenopausal woman with osteopenia from PHPT faces progressive bone loss and fracture risk if left untreated.
Pre-Surgical Workup Required
Before surgery, complete the following assessments 1:
Renal evaluation:
- Low-dose CT urography (preferred) or renal ultrasound to assess for nephrolithiasis or nephrocalcinosis
- 24-hour urine calcium to identify hypercalciuria (another surgical indication)
Parathyroid localization studies:
- First-line: Parathyroid ultrasound
- Combined with either:
- Double isotope scintigraphy (123I/99mTc-Sestamibi), OR
- 18F-Choline PET-CT
If these studies fail to localize the adenoma, refer to an expert center for MRI or 4D CT 1.
Critical Caveat About Vitamin D
While your patient's vitamin D is adequate at 60 ng/mL, do NOT supplement with additional vitamin D preoperatively. Although vitamin D supplementation can be beneficial in PHPT patients with deficiency 3, there is documented risk of unmasking severe hypercalcemia when repleting vitamin D in PHPT patients 4. Since this patient already has sufficient levels, additional supplementation could precipitate a hypercalcemic crisis.
The one exception: if vitamin D were deficient, correction would be recommended specifically to prevent postoperative hungry bone syndrome, but only in patients with calcium <3.5 mmol/L (14 mg/dL) 1.
Why Not Medical Management?
Medical management with bisphosphonates or cinacalcet is reserved for patients who "cannot or do not want to undergo surgery" 5. These are second-line options:
- Bisphosphonates (like alendronate) improve BMD but don't address the hypercalcemia
- Cinacalcet lowers calcium but doesn't improve BMD and has only modest effects on PTH 5
Since your patient is a surgical candidate with a clear indication (osteopenia), definitive treatment with parathyroidectomy is superior—it addresses both the hypercalcemia and prevents further bone loss.
Surgical Referral
Refer to an experienced endocrine surgeon 1. The surgery should be performed at a center with expertise in parathyroid surgery, as outcomes are operator-dependent. If localization studies are negative or equivocal, refer to an expert center before attempting surgery 1.